Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + chidamide + adebrelimab for unresectable locally advanced or metastatic renal cell carcinoma
ChiCTR2500095466Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib, tucidinostat and adebrelimab in renal cell carcinoma (RCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
pazopanibtucidinostatadebrelimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2500095466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095466.